To The Moon

1."Miracle Weight Loss Drug" Finds a New Purpose

$Eli Lilly(LLY)$ ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.

This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.

Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪

Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says

2. If Zepbound proves effective for sleep apnea in trials, it could benefit:

• Sleep Apnea Patients: 😴 Great news for those seeking new treatments!

• Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one therapeutic effect.

• Healthcare Providers: 🩺 Doctors may have a new option for treating sleep apnea.

• Investors: if the new use of Zepbound is approved, it could positively impact $Eli Lilly(LLY)$ 's stock price.

However, the "need" for this drug depends on various factors, including individual health conditions, medical advice, and the drug's final approval status. It's crucial to consult with healthcare professionals and understand the potential benefits and risks before considering any new medication.

As for whether it continues to be a positive for Eli Lilly, it will depend on several factors, including but not limited to:

• 🧪 Trial Results: Key outcomes for sleep apnea treatment.

• 🏛️ Regulatory OK: FDA and other approvals needed.

• 📈 Market Reception: Doctors' and patients' adoption of the drug.

• 📊 Go-to-Market Plan: Eli Lilly's pricing and promotion strategy.

Investors should consider these factors and conduct thorough market research and risk assessment before making investment decisions.

3. $Eli Lilly(LLY)$ Faces a Supply Shortage Expected in the Q2 24

🌟 FDA Update: There's a shortage of most dosages for Eli Lilly's popular weight loss drug Zepbound and diabetes treatment Mounjaro, except the 2.5 mg versions, due to skyrocketing demand.

💊 Supply Status: All dosages, except for the 2.5 mg, are currently hard to come by. Earlier reports indicated limited supply through April.

📈 Production Efforts: Even with $Eli Lilly(LLY)$ and competitor $Novo-Nordisk A/S(NVO)$ stepping up production, the demand for these in-demand weight loss and diabetes drugs is putting a strain on supply.

💬 Eli Lilly's Response: "We recognize this could disrupt treatments, and we're working diligently to satisfy the high demand," said a company spokesperson. They added, "Our manufacturing and supply chain investments should help us gradually increase production from 2024 and beyond."

4. $Eli Lilly(LLY)$ Q124 earnings report is expected before the market opens on April 30, 2024.

📊 Eli Lilly's Q4 2023 Earnings:

• Revenue: $9.35 billion 📈

• Net Income: $2.19 billion,up from1.94 billion last year 💹

🔮 2024 Forecast:

• Revenue: $40.4billion to $41.6 billion

• Diluted Earnings per Share: $11.80 to$12.30

• Non-GAAP Diluted Earnings per Share: $12.20 to$12.70 📉

📅 Next Earnings Report: April 30, 2024, before market open for Q4 ending March 2024.

• Analysts' Consensus EPS Forecast: $2.53,up from $1.62 last year's quarter 🌠

Stay tuned for Eli Lilly's upcoming earnings and how they'll shape the company's future! 🔍💼

LLY Monthly Chart

5. 📊 Investor Insight: $Eli Lilly(LLY)$

Data from MarketBeat.com

• Price Target: $Eli Lilly(LLY)$ ′s average target is $728, with a high target of $1000.It′s currently trading at a high of $800.

• Production Expansion: A new NC factory is set to produce incretin-based drugs by year-end, with a German and two Indiana factories in the pipeline.

• Market Position: $Eli Lilly(LLY)$ now boasts a marketcap of $713.81 billion, ranking it 11th in the U.S. stock market.

• Strategic Outlook: With these expansions, $LLY is positioning for growth.

Whether the current momentum justifies the optimistic outlook. Are you continued optimism for $Eli Lilly(LLY)$ ?

Share your investment thesis. 💼🔍